London-based Webiny nabs €2.9 million to help developers build serverless solutions in minutes

EU-Startups

Charlotte Tucker (eu-startups.com)

London-based Webiny, an open-source platform providing developer tools, libraries, ready-made apps and processes specifically created for serverless development, has raised €2.9 million in a seed funding round led by Microsoft’s venture arm M12, with notable participation from Samsung Next, Cota Capital, Episode 1 and YCombinator.

Founded in 2019, Webiny was originally conceived in the context of a serverless content management system. However, the startup states that as users and customers began requesting to use its serverless platform for more, such as building full-stack applications, scalable and performant APIs and fully control the security aspects around those, they pivoted. Webiny became a platform to help companies adopt serverless within their organisations..

With feedback from hundreds of organisations that have tried out Webiny, they decided to split Webiny into 2 different products. The serverless CMS, from before, and a new serverless application framework focusing on building full-stack apps and GraphQL APIs.

Webiny’s serverless application framework provides developers with a performant and ready-made architecture running on fault-tolerant serverless infrastructure, designed to handle millions of users. Previously, to reach this level of performance, scalability and redundancy, organisations had to have entire teams of experts to build and manage such a solution, now, these capabilities are available within minutes.

Having now closed this funding round, the team will use the boost to develop its platforms further, and improve their documentation and developer experience.

Sven Al Hamad, CEO and co-founder, commented in a recent statement: “None of this would have been possible without a team that truly believes in our mission supported by our existing investors and advisors. It’s a combination of many great things that came together at the right point in time, fueled by the amazing support and feedback coming from our amazing community.”

Original Article

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs

BusinessLive

By BusinessLive

Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital

Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications

OXFORD, England–(BUSINESS WIRE)–Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes. The Series B financing was initially set at $50m and was upsized to $80m due to overwhelming interest from investors to support Beckley Psytech in broadening and accelerating the clinical development of its innovative research pipeline.

Beckley Psytech will use the proceeds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression. The funding will also support the expansion of the company’s pipeline with new, unique and proprietary psychedelic compounds.

The financing round is led by Integrated, a healthcare focused VC which partners with companies and entrepreneurs that are transforming the health and well-being of communities around the globe. The science-focused investor consortium includes Prime Movers Labs, which funds breakthrough scientific startups; Adage Capital Management LP, a Boston based institutional investor; Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.

Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “My life’s passion has been to unlock the therapeutic potential of psychedelics as I believe these compounds could help millions of people around the world. The progress Beckley Psytech has made in attracting exceptional talent to the team and advancing our ambitious clinical development programmes over the past two years has been tremendously exciting. As we embark on our next phase of growth, our strong syndicate of expert investors will support us in bringing much-needed innovative treatments to patients suffering from neurological and psychiatric conditions.”

Jay Newmark, general partner of Integrated, commented: “Cosmo and his dedicated team at Beckley Psytech have created an exceptional research and development platform. Their highly differentiated approach, which treats not only large indications such as depression but also rare indications such as SUNHA, is allowing accelerated access to market. We deeply appreciate our value alignment with this team and eagerly anticipate their progress in improving access to these medicines.”

Dr Amy Kruse, partner, Prime Movers Lab, said: “It is nearly impossible to find a team with more experience in developing psychedelic medicines for neurological conditions than the one at Beckley Psytech. The COVID-19 pandemic brought mental health to the public’s attention in a profound way. The excitement around psychedelics in the mental health market is very real because they are transformative medicines that will soon make their way into the lives of millions of people who desperately need them.”

Original Article

Collective raises £6m with Silicon Valley NFX, amid growing demands for gig worker benefits

CityAM

Farah Ghouri (cityam.com)

Collection Benefits, a UK insurance tech startup, have raised £6m in a round led by a Silicon Valley venture fund, as the demand for insurance and benefits in the gig economy continues.

The year-old insurance provider also announced the appointment of Pete Flint OBE, the co-founder of Lastminute.com and a general partner at NFX, as a new board member.

Collective is an insurance provider designed specifically for independent, freelance workers in the gig economy which also works directly with on-demand platforms such as TaskRabbit.

Since being founded the company has insured 200,000 people across 20 countries with flexible insurance and benefits specifically for independent workers, from sick and injury pay to family and compassionate leave.

The London-based insurtech said the investment will help fuel its expansion across Europe as it continues to fill the gap between the flexibility of gig work with the lack of protections independent work naturally comes with, with insurance cover.

The business said the injection of cash will allow it to create more products, such as public liability insurance and pensions, to protect independent workers’ physical, mental and financial wellbeing.

Pete Flint OBE, general partner at NFX said: “We like to partner with the startups that will define their category.”

He described the insurtech company’s services as “the missing safety net for independent workers – in a way that creates a win-win outcome for both independent workers themselves, and the platform companies they work with.”

The investment in Collective will be “an opportunity to transform both the insurance and the on-demand economy” with a blend of ground-breaking tech and razor-sharp insurance capabilities,” said Flint.

It comes a year after Collective raised a £3.3m seed round, taking the total raised since it was founded to just under £10m.

Alongside NFX, Collective has enjoyed continued support from investors including Stride VC, Delin Ventures, Insurtech Gateway and executives from Uber, Just Eat and Urban.

Collective chief executive officer Anthony Beilin said “We see NFX’s investment in Collective as a major vote of confidence in our ability to solve the protection gap problem for tens of millions of independent workers across the UK and Europe.”

Beilin, who is also a co-founder of the startup, came up with the idea of an insurance solution for independent workers while he was himself on sick leave with a host of generous benefits from a large corporate insurer.

Original Article

Direct-to-consumer orthodontic startup Impress raises $50M to scale across Europe

TechCrunch

By Mike Butcher (techcrunch.com)

As the famous phrase goes, “software is eating the world” — and now software is eating dentistry. Or, perhaps more accurately, the arena of orthodontics — the specialty of dentistry that deals with things like braces — is slowly but surely being digitalized.

To whit, Impress, a Southern European player in direct-to-consumer orthodontics, has raised a $50 million Series A funding round led by CareCapital (a dental division of Hillhouse Capital in Asia), along with Nickleby Capital, UNIQA Ventures and investors including Michael Linse, Valentin Pitarque, Peter Schiff, Elliot Dornbusch and others. All existing shareholders, such as TA Ventures and Bynd VC, also participated.

Impress is an homage to the direct-to-consumer startups in this area in the U.S., such as SmileDirect, and now plans to scale across Europe from its existing bases in Spain, Italy, Portugal, the U.K. and France.

The company was founded in 2019 in Barcelona by orthodontist Dr. Khaled Kasem and serial entrepreneurs Diliara and Vladimir Lupenko.

Speaking from Barcelona, Lupenko told me that the idea was to “combine the best orthodontic tradition with the most innovative technology in the sector.”

As things stand, most of the time, consumers can usually only access cosmetic teeth alignment treatments or orthodontic medical treatments in conventional clinics. The new wave of clinics employs 3D scans and panoramic X-rays to check nerve and bone health.

Impress’s model is to offer these high-quality medical treatments directly to consumers, by developing its own chain of orthodontic clinics, which also put an emphasis on design and a “modern” patient experience, it says.

As Diliara Lupenko says: “We didn’t copy what other companies in the space were doing and approached the market from a different angle from the get-go. We doubled down on the doctor-led digital model which brought us way better conversion rates and treatment quality even though on paper it looked complex in the beginning. It’s still very complex but we were able to crack it and scale exponentially.”

Impress now has 75 clinics in Spain, Italy, the U.K., France and Portugal, which optimize costs and automate key parts of the value chain.

It now says it’s approaching €50 million in annual run-rate and is projected to grow to €150 million of revenue in 12 months.

Andreas Nemeth, managing partner of UNIQA Ventures GmbH commented: “Impress’s customer-centric focus, as well as its demonstrated ability to blitzscale, attracted us to the business. Vladimir and his team leverage technology to create a seamless customer journey for invisible orthodontics and optimized their cost structure in a unique way using software.”

Original Article

Buy-now pay-later for household bills Deferit raises $15m in Series B

Business News Australia

By Buiness News Australia

An oversubscribed Series B funding round raising $15 million will accelerate international growth and bolster the team of Sydney-based bill payment platform Deferit.

Led by existing investor Carthona Capital and new investor Alceon Group, the $15 million raise will give the buy-now pay-later (BNPL) platform for bills a shot in the arm, after Deferit witnessed 150 per cent growth in the past 12 months.

The platform, which doesn’t fund discretionary purchases but helps users manage household bills such as telecommunications, energy and car registrations, has already passed milestones of 250,000 users and helped Australians pay off over $100 million in bills.

Deferit CEO and co-founder Jonty Hirsowitz (pictured right) said the funds would be used to accelerate the company’s growth via marketing and partnerships, and to grow its team with new hires.

“Our total focus is executing our vision to help more Australian’s pay more bills on time and we’re delighted with the support of Carthona Capital and our existing and new investors including Alceon Group,” Hirsowitz said.

According to co-founder Mat Blas (pictured left), Deferit addresses a unique segment of the BNPL market, giving customers flexibility with bill payments by enabling them to be paid off in four fortnightly instalments.

“In the bill payment vertical we’re addressing a different consumer need and pain point,” says Blas.

“Consumers want and need flexibility around moving their payment dates and getting their budget on track and that’s what we’re allowing users to do: across all major billers; as any bill arrives; at the click of a button.”

“The Deferit team led by Jonty Hirsowitz and Mat Blas have proven they can scale the business and manage risk and we believe they have the product and vision to make Deferit a lead player in the $211B Pay Later vertical of everyday bills,” adds Carthona Capital partner Dean Dorrell.

Original Article

Beckley secures landmark clinical trial approval

Berkley Psytech

By Beckley Psytech

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition.

The upcoming Phase 1B study plans to enrol up to 12 patients suffering from SUNHA, a disease belonging to a group of headache disorders called the Trigeminal Autonomic Cephalalgias (TACs), considered one of the most painful disorders known to mankind and estimated to affect approximately 46,000 patients in the US, Canada and the G5 from Europe. There are currently no approved treatments for SUNHA, which is characterized by short-lasting headaches that range from severe to excruciating and may occur over 100 times a day.

This landmark clinical trial, the first researching the effect of psilocybin on SUNHA patients, will evaluate the potential therapeutic benefits of the psychedelic compound in treating this disabling condition. Beckley Psytech is also evaluating the use of wearables for data capture in this clinical trial.

Approval of Beckley Psytech’s psilocybin clinical trial is the latest achievement in its mission to develop a fully licensed psychedelic medicine pipeline, following the company’s successful private fund raising of £14m in December 2020. The company is also developing synthetic 5-MeO-DMT, a unique psychedelic agent with a short duration of action, in the treatment of neuropsychiatric diseases, expected to enter the clinic in 2021.

Original Article

LoveFilm co-founder backs former army officer startup in £1.3M funding to protect people’s privacy

uktech.news

By Staff Reporter (uktech.news)

Investors including Force Over Mass Capital, the FCA regulated venture capital firm focused on early stage technology investments across the UK and Europe, Simon Franks one of the co-founders of LoveFilm, Eric Salama former CEO of Kantar and Innovate UK have recently came together to back a new London-based startup Glimpse Protocol.

The tech startup was founded by Mark Stoter OBE, a former British Army Intelligence officer, and his cyberwarfare colleagues. They’re taking a stand to protect people’s privacy by developing new tech that delivers accurate digital ads without the need for consumer data.

Raised £1.3 million

Glimpse Protocol has secured a £1.3 million seed investment round which the company plans to use to grow its engineering team and capitalise on the success of pilots completed across 2020.

Mark Stoter OBE, CEO, and co-founder said, “Our vision for Glimpse Protocol is to set new standards for privacy in advertising, becoming the kitemark that consumers can trust. This investment will enable us to roll out our technology that delivers valuable, effective advertising while respecting consumer privacy. With consumers, regulators, and tech giants taking action on data privacy, the digital advertising industry is seeking a solution that can weather technical changes and increasingly stringent privacy requirements. Unlike our competitors, who offer partial stopgaps, Glimpse Protocol provides a uniquely clear vision of how the problem can and must be tackled.”

He launched the company in 2019 along with Tim Holmes-Mitra MBE, and Alasdair Macdonald to tackle digital advertising’s biggest challenge: ensuring brands can reach their customers without breaching their privacy or the law.

Basically, Glimpse Protocol uses a unique combination of edge processing and novel cryptography to ensure consumers can never be traced or de-anonymised.

By guaranteeing privacy and cutting out 3rd party data sources, the UK company offers +30% ROI to brands and can extend reach to previously closed-off audiences.

Simon Franks, the investor, said: “Digital advertising needs to be re-shaped both for the good of the public and also for advertisers. Glimpse Protocol’s approach is exciting and timely and has the potential to disrupt an industry by allowing advertisers to reach the audiences they need but in an ethical way that respects consumer privacy and pays publishers a fair price. It’s a real breakthrough and I’m convinced that they will be both a commercial success but also a champion for the consumer. I am very proud to be a part of their journey.”

Eric Salama, investor and former CEO of Kantar, said: “I’m delighted to participate in Glimpse’s seed round. Consumer Privacy is becoming a more and more central issue by the day and Glimpse is one of the few platforms combining effective advertising tools with complete respect for consumer privacy. It allows the ad industry to serve brands and publishers in an ethical way.”

Glimpse Protocol has already developed an exciting partnership with Iconic Labs Plc giving access to premium platforms including JOE Media. Commenting on the collaboration, Iconic Labs COO Samuel Regan Asante commented, “We are excited by our partnership with Glimpse Protocol who are leading the way in cookie-less technologies in the Adtech industry. Iconic Labs is aiming to establish itself as a leader in both the tech and media fields and Glimpse Protocol’s technology presents the perfect balance of the two.”

Further, Glimpse Protocol is a Tech Nation Rising Star regional 2020 winner and a participant in the Founders Factory accelerator programme.

Original Article

Fast grocery delivery app Weezy plots expansion after $20m fundraise

thegrocer.co.uk

By Alec Mattinson (thegrocer.co.uk)

UK-based fast grocery delivery app Weezy is planning to roll out its services across London and further afield after raising $20m (£14.7m) in growth funds.

The app-based supermarket, which promises groceries within 15 minutes of ordering began to deliver in London during the summer after securing £1m pre-seed investment.

Now it is looking to scale up operations after raising $20m in Series A funding, led by New York-based venture capital fund Left Lane Capital.

Also participating are UK-based fund DN Capital, earlier investors Heartcore Capital and angel investors, notably Groupon founder Chris Muhr.

The funding will help expand the company’s London-based team by 50 employees over the next four months, in addition to extra fulfilment centre staff.

Weezy is opening two fulfilment centres in Lambeth and London Fields this month, adding to its existing locations covering Battersea, Clapham, Fulham and Chelsea.

It plans to open 40 more UK sites by the end of 2021.

Since its launch in July 2020, Weezy has delivered fresh produce and household items to thousands of customers, using pedal cycles or electric mopeds, in less than 15 minutes on average charging £2.95 per delivery.

Weezy helps busy householders to shop for groceries quickly and says it “has proved to be a lifeline for all age groups during the coronavirus pandemic”.

Kristof Van Beveren, co-founder and CEO of Weezy, commented: “People are no longer happy to wait around for deliveries, and there is strong demand for a more efficient service. Weezy customers love the friendliness of our team, the quality of our produce, and our quick, accurate delivery times. This new funding round will allow us to expand the team and our footprint to bring Weezy to more customers across the UK.”

Harley Miller, managing partner of Left Lane Capital, added: “Weezy’s founding team have the right balance of drive, experience and temperament to lead in e-commerce innovation and convenience within the UK grocery market and beyond. It is an honour to partner with them on this journey and help them solidify their first-mover advantage in London.”

Seed investors in the business include former Ocado head of retail Jon Rudoe, who as digital and technology director at Sainsbury’s founded Chop Chop and SmartShop; and Onefinestay co-founder Greg Marsh, an early backer of Deliveroo.

Original Article

UK-based Beckley Psytech raises £14 million to advance drug discovery to clinical trials

tech.eu

By Annie Musgrove (tech.eu)

Beckley Psytech, a UK psychedelic medicine company with ties to drug policy think tank the Beckley Foundation, has raised £14 million to turn certain drugs into licensed pharmaceutical medicines.

The equity round, which follows on from £3 million of funding raised in May, comes from Noetic Psychedelic Fund and Bail Capital, who are joining existing investors Jim Mellon and Richard Reed.

This investment will help the company power through its drug development pipeline, specifically exploring the use of 5-MeO-DMT, a synthetic substance that could treat neuropsychiatric diseases. The company is actually preparing to begin its Phase 1 clinical trial – a ground-breaking regulatory standard clinical trial on 5-MeO-DMT.

The team will also explore other psychedelic agents that could treat so-called ‘orphan diseases’, those that are too rare to be lucrative enough for typical pharmaceutical companies.

Beckley Psytech was founded last year by long-time psychedelic researcher Lady Amanda Feilding and CEO Cosmo Feilding Mellen, as a spin-out of the foundation that’s been around since 1998. Its Scienctific Advisory Board includes Dr. Robin Carhart-Harris from Imperial College London, Prof. Matthew Johnson from Johns Hopkins University and Prof. Guy Goodwin from the University of Oxford.

Original Article

Ouster, maker of self-driving tech, agrees $1.9 billion deal to go public

reuters.com

By Joshua Franklin, Paul Lienert (reuters.com)

(Reuters) – Ouster Inc, a U.S. startup that makes lidar sensors for self-driving cars and smart cities, said on Tuesday it has agreed to go public through a merger with special purpose acquisition company (SPAC) Colonnade Acquisition Corp.

The deal values San Francisco-based Ouster at around $1.9 billion and makes it the fifth lidar manufacturer this year to agree a SPAC merger to go public, following on from Velodyne Lidar Inc, Luminar, Innoviz and Aeva.

Ouster sees its digital lidar technology as having practical applications beyond autonomous vehicles and extending to areas such as drones, smart cities and robotics, according to company co-founder and Chief Executive Angus Pacala.

“The vision of the future that we’re pushing towards is lidar on every vehicle on earth, every moving object on earth and every piece of intelligent fixed infrastructure on earth, in the same way that camera technology has propagated and become ubiquitous in the last 20 years,” Pacala said in an interview, speaking with Colonnade Chief Executive Remy Trafelet.

Reuters had reported earlier that Ouster and Colonnade were nearing a merger agreement.

SPACs like Colonnade are increasingly popular investment vehicles which raise funds in an initial public offering (IPO) with the aim of buying a private company. The acquired company then becomes public as result of the merger and is an alternative to the traditional IPO process.

Colonnade raised $200 million in an IPO in August. For the deal with Ouster, Colonnade also raised $100 million through a private investment in public equity, or PIPE, transaction. Investors in the PIPE included Cox Automotive, Fontinalis Partners, and WWJ Enterprises.

Overall the deal will bring in up to $300 million in gross proceeds for Ouster.

Ouster, which expects to generate around $19 million in revenue in 2020, stood out from other companies in the space that Colonnade had looked at buying because its business is already generating revenue, Trafelet said.

“It’s not a business plan – they’re selling real products to real customers right now,’ he said.

Lidar sensors, which use laser light pulses to render precise images of the environment around the car, are seen as essential by many automakers to allow higher levels of driver assistance right up to making them capable of self-driving.

Five-year-old Ouster had previously raised $142 million from private market investors, including Cox , Silicon Valley Bank and Fontinalis, which is co-owned by Ford Motor Executive Chairman Bill Ford.

Original Article